Table 3.
Study | 1-Year post-operative mortality (%) | p value | Overall complication rate (%) | p value | Overall rate of reoperation | p value | Overall rate of peri-prosthetic fractures | p value | Overall rate of peri-prosthetic infections | p value | 1 Year post-operative harris hip score (SD) | p value | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hulet et al.21 | Short | 33 (47.14%) | NI | 19 (27.14%) | NI | NI | NI | 0 (0.00%) | NI | NI | NI | NI | NI |
Long | 41 (31.30%) | 34 (25.95%) | NI | 0 (0.00%) | NI | NI | |||||||
Krigbaum et al.22 | Short | 35 (28%) | 0.33 | 21.0% | 0.710 | 5.00% | 0.120 | NI | NI | NI | NI | NI | NI |
Long | 47 (34%) | 19.0% | 1.00% | NI | NI | NI | |||||||
Kleweno et al.23 | Short | NI | NI | 80 (36.5%) | 0.930 | 7 (3.20%) | 0.810 | 6 (2.70%) | 0.35 | NI | NI | NI | NI |
Long | NI | 122 (35.9%) | 12 (3.50%) | 5 (1.50%) | NI | NI | |||||||
Hou et al.18 | Short | 22 (22.0%) | 0.785 | 10 (10.0%) | 0.518 | 5 (5.0%) | 0.809 | 0 (0.00%) | 0.178 | 1 (1.00%) | 0.942 | NI | NI |
Long | 42 (23.0%) | 23 (12.6%) | 8 (4.4%) | 2 (1.10%) | 2 (1.10%) | NI | |||||||
Frisch et al.24 | Short | NI | NI | NI | NI | NI | NI | 6 (8.30%) | 0.013* | 1 (1.40%) | 0.637 | NI | NI |
Long | NI | NI | NI | 0 (0.00%) | 3 (3.10) | NI | |||||||
Vaughn et al.12 | Short | NI | NI | 4 (6.63%) | NI | NI | NI | 2 (3.33%) | NI | NI | NI | NI | NI |
Long | NI | 9 (4.60%) | NI | 0 (0.00%) | NI | NI | |||||||
Boone et al.25 | Short | NI | NI | NI | NI | NI | NI | 1 (0.84%) | NI | NI | NI | NI | NI |
Long | NI | NI | NI | 0 (0.00%) | NI | NI | |||||||
Guo et al.26 | Short | NI | NI | 3 | > 0.05 | NI | NI | 1 (0.90%) | NI | 1 (0.90%) | > 0.05 | NI | NI |
Long | NI | 4 | NI | 1 (1.30%) | 1 (1.30%) | NI | |||||||
Sellan et al.27 | Short | 11 (15.5%) | 0.783 | 39 | NI | NI | NI | 5 (7.00%) | 0.35 | NI | NI | NI | NI |
Long | 5 (12.8%) | 27 | NI | 1 (2.60%) | NI | NI | |||||||
Okcu et al.28 | Short | 3 (16.6%) | 0.9 | 3 (20.0%) | 0.390 | 0 | 0.410 | NI | NI | NI | NI | 74 (8) | 0.11 |
Long | 5 (18.1%) | 6 (33.3%) | 2 | NI | NI | 79 (10) | |||||||
Hong et al.29 | Short | 2 (4.50%) | 0.625 | NI | NI | 4 (9.10%) | 0.689 | 3 (6.80%) | NI | NI | NI | NI | NI |
Long | 0 (0.00%) | NI | 1 (5.00%) | 0 (0.00%) | NI | NI | |||||||
Sadeghi et al.20 | Short | NI | NI | NI | NI | 46 (1.90%) | NI | 14 (0.60%) | NI | 1 (2.20%) | NI | NI | NI |
Long | NI | NI | 50 (1.60%) | 13 (0.40%) | 0 (0.00%) | NI | |||||||
Li et al.30 | Short | NI | NI | 3 (3.00%) | < 0.05* | NI | NI | NI | NI | NI | NI | 76.16 (10.84) | 0.28 |
Long | NI | 0 (0.00%) | NI | NI | NI | 79.98 (8.9) | |||||||
Raval et al.31 | Short | 3 (7.50%) | 0.456 | NI | NI | 1 (2.50%) | 0.556 | NI | NI | NI | NI | NI | NI |
Long | 5 (12.50%) | NI | 2 (5.00%) | NI | NI | NI | |||||||
Bovbjerg et al.32 | Short | NI | NI | 5 (5.25%) | NI | NI | NI | 1 (1.05%) | NI | 0 (0.00%) | NI | NI | NI |
Long | NI | 7 (5.80%) | NI | 1 (0.83%) | 0 (0.00%) | NI | |||||||
Shannon et al.33 | Short | NI | NI | 12 (15.5%) | 0.830 | 5 (6.25%) | 0.720 | 2 (2.49%) | 1 | 1 (1.25%) | 1 | 76 (3 months) (IQR 74–78) | 0.02* |
Long | NI | 12 (13.60%) | 8 (9.09%) | 2 (2.27%) | 2 (2.27%) | 71 (3 months) (IQR 68,074) |
NI no information.
*Indicates statistically significant difference reported.